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Summary
Background: Spondyloarthritis is the most frequent extra‐intestinal manifestation 
of IBD.
Aim: To present simple strategies to identify and differentiate inflammatory joint pain 
in IBD patients.
Methods: A panel of Belgian gastroenterologists and rheumatologists developed 
seven algorithms for IBD patients with joint symptoms based on a Delphi exercise 
conducted between April and December 2016. Here, we focus on referral strategies 
for patients with chronic back pain (evidence‐based strategy), large joint monoar‐
thritis, oligo‐ or polyarticular arthritis or arthralgia (based on expert opinion). We 
also present management tools for IBD patients with acute back pain and small joint 
monoarthritis (Supplementary file).
Results: The reported algorithm for IBD patients with chronic back pain uses basic 
clinical criteria to identify which patients should be referred to the emergency room 
(spondylodiscitis), physical medicine and rehabilitation (mechanical back pain) or 
rheumatologist (spondyloarthritis). IBD patients with large joint monoarthritis should 
be referred to emergency room if septic arthritis is suspected; in other patients, blood 
analyses and referral to a rheumatologist for articular puncture with evacuation of 
synovial fluid are recommended. The analysis of synovial fluid allows for identifica‐
tion of non‐inflammatory (e.g., osteoarthritis) and inflammatory (e.g., [pseudo]‐gout, 
peripheral spondyloarthritis and Borrelia burgdorferi arthritis) conditions. In patients 
with inflammatory oligoarticular or polyarticular arthralgia, erythrocyte sedimenta‐
tion rate, concomitant therapies, anti‐nuclear factor and anti‐double‐stranded DNA 
antibody levels should be evaluated; in anti‐tumour necrosis factor‐treated patients, 
a drug‐induced lupus‐like syndrome should be considered.
Conclusion: We propose straightforward strategies for IBD patients with joint symp‐
toms, which are specific enough to select initial treatment and referral pattern.
     |  1205VARKAS et Al.
1  | INTRODUC TION
IBD, including Crohn's disease and ulcerative colitis, affects not only 
the gut but also extra‐intestinal sites in approximately one‐third of 
patients, predominantly the skin and the joints.1,2 The most frequent 
extra‐intestinal manifestation of IBD is spondyloarthritis,1 a group 
of articular chronic inflammatory diseases, including ankylosing 
spondylitis, psoriatic arthritis, reactive arthritis, IBD‐related spon‐
dyloarthritis, and undifferentiated spondyloarthritis.3 IBD and spon‐
dyloarthritis are associated in genetic background, and in clinical and 
imaging features.4‐6
Depending on the predominant manifestation, spondyloarthritis 
is divided into axial spondyloarthritis and peripheral spondyloarthri‐
tis.7 The early diagnosis of spondyloarthritis may be a major chal‐
lenge for physicians due to the lack of objective disease markers.8,9 
Moreover, joint symptoms usually occur in patients treated with 
immunomodulatory drugs, masking clinical presentation.7 In axial 
spondyloarthritis, the main symptom is chronic (low) back pain in‐
duced by inflammation of the sacroiliac joints (sacroiliitis) or spine 
(spondylitis). In some patients, axial spondyloarthritis evolves into 
ankylosing spondylitis, a more severe disease stage with structural 
damage of the sacroiliac joints and/or spine visible on X‐ray.10,11 The 
main symptoms of peripheral spondyloarthritis are arthritis, enthesi‐
tis and dactylitis.12
A recent meta‐analysis has shown that up to 13% of IBD patients 
are diagnosed with peripheral arthritis, whereas prevalence esti‐
mates for sacroiliitis and ankylosing spondylitis are 10% and 3%, re‐
spectively.12 Joint flares usually, but not exclusively, accompany gut 
flares.13,14 Although sacroiliitis can be seen on X‐ray and computed 
tomography of the abdomen in IBD patients,15‐17 recent studies have 
shown that magnetic resonance imaging is superior to detect inflam‐
matory sacroiliitis and allows an earlier diagnosis of axial spondyloar‐
thritis, before the occurrence of structural changes.18,19 However, 
the abnormalities of the sacroiliac joints present on magnetic res‐
onance enterography were not associated with inflammatory back 
pain (IBP).19 Therefore, imaging findings should be interpreted cau‐
tiously in asymptomatic patients. Indeed, the significance of subclin‐
ical sacroiliitis is unknown and research has mainly focused on the 
diagnosis and treatment of symptomatic patients.
Considering the high prevalence of rheumatic diseases in IBD 
patients, the difficult diagnosis of spondyloarthritis and the short‐
age of rheumatologists, there is a need for feasible and simple refer‐
ral strategies, sensitive and specific enough to select patients with 
rheumatic conditions suggestive of spondyloarthritis.
2  | MATERIAL S AND METHODS
This paper has been developed based on a Delphi exercise amongst 
a panel of experts in the field of spondyloarthritis and/or IBD be‐
tween April and December 2016.
First, the development of referral algorithms for IBD patients 
with joint symptoms was initiated by experts from the University 
of Ghent, who drafted initial referral proposals based on expert 
opinions, scientific literature and clinical experience. The relevant 
literature was selected through a thorough PubMed search, based 
on the following terms and their combinations: “inflammatory bowel 
disease”, “arthritis”, “sacroiliitis”, “arthralgia”, “referral”, “spondyloar‐
thritis” and “ankylosing spondylitis”.
Secondly, a panel of eight interuniversity specialists in the field 
of IBD and spondyloarthritis, including Belgian gastroenterologists 
and rheumatologists from the Universities of Ghent, Leuven and 
Liège, were selected to attend a consensus meeting on May 2, 2016. 
Pairs of gastroenterologists and rheumatologists from the three 
universities discussed the proposed referral algorithms for common 
joint symptoms in IBD patients, such as acute back pain, chronic 
back pain, large joint monoarthritis, small joint monoarthritis, oligo‐ 
or polyarthritis, monoarticular arthralgia and oligo‐ or polyarticular 
arthralgia. Based on the critical appraisal of the experts, the referral 
algorithms were revised. Updated proposals were shared with all ex‐
perts who could provide additional feedback via email. Finally, the 
proposed referral algorithms were presented and tested for feasi‐
bility and applicability in a national meeting with nonselected gas‐
troenterologists on December 2, 2016, leaving room for additional 
remarks from the audience.
Here, we focus on referral algorithms for IBD patients with 
chronic back pain, large joint monoarthritis and arthralgia, which are 
the most frequently encountered topics in clinical practice.
3  | RESULTS AND DISCUSSION
3.1 | Axial spondyloarthritis
Although axial spondyloarthritis is a common cause of chronic low 
back pain in IBD patients, its early diagnosis remains challenging. 
The proposed evidence‐based referral algorithms for IBD patients 
with back pain are largely based on an existing algorithm developed 
for the overall population, but have been adapted to IBD patients 
taking into account their treatment.8
3.1.1 | Exclusion of spondylodiscitis
In IBD patients taking immunosuppressants, infectious spondylo‐
discitis must be excluded in case of new‐onset back pain. In case 
of fever, high inflammatory parameters, infectious focus or neuro‐
logical symptoms, immediate referral to the emergency room with 
a diagnostic work‐up is advised. Magnetic resonance imaging of 
the spine is recommended. Potential causative pathogens should 
be identified by blood culture or biopsy before initiation of treat‐
ment with antibiotics.20 An extensive review of treatment options 
for spondylodiscitis is beyond the scope of this article.
3.1.2 | Acute vs chronic back pain
Acute back pain is defined as back pain with a duration of less than 
6 weeks.21 Although lumbalgia and ischialgia are common in the 
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setting of strain or trauma, acute back pain can have inflammatory 
features resembling inflammatory back pain. However, unlike strain 
and trauma, sacroiliitis or spondylitis will usually not result in antal‐
gic posture or limping. Likewise, neurologic symptoms are more in‐
dicative of degenerative disc disease, spinal canal stenosis or pain 
originating from facet joints. A referral strategy for IBD patients with 
acute back pain can be found in Figure S1. Overall, acute back pain 
is rarely caused by rheumatologic conditions, and patients should be 
referred to other musculoskeletal specialists.
Chronic back pain is generally defined as back pain with a dura‐
tion of at least 6‐12 weeks. 21 Although back pain is often the main 
complaint in axial spondyloarthritis, only 5% of patients with chronic 
back pain have underlying axial spondyloarthritis.22,23 However, 
the prevalence of axial spondyloarthritis is higher in patients with 
chronic back pain and a closely related disease, such as IBD.12
3.1.3 | Referral strategy for IBD patients with 
chronic back pain
Based on an algorithm previously developed to assist in the early 
diagnosis of axial spondyloarthritis in all patients with chronic back 
pain,8 we designed an adapted referral algorithm for IBD patients. 
Our decision tree was supported by calculations of post‐test prob‐
abilities by applying formulas based on Bayes’ theorem, as described 
in the original article.8
The previously developed algorithm utilises average represen‐
tative sensitivities and specificities of several spondyloarthritis 
features, which were collected from the literature. As recognition 
of some of the spondyloarthritis features may be difficult for phy‐
sicians who are less familiar with rheumatic disease, we simplified 
the algorithm to include inflammatory back pain, response to non‐
steroidal anti‐inflammatory drugs (NSAIDs) and human leucocyte 
antigen (HLA)‐B27 status, which are important and well‐known 
spondyloarthritis characteristics. C‐reactive protein (CRP) elevation 
was not included because IBD may account for elevated CRP levels 
regardless of concomitant spondyloarthritis. As our tool will be used 
for screening, sensitivity was prioritised.
The cardinal symptom in axial spondyloarthritis is inflammatory 
back pain, which is present in most patients (Figure 1).24 Different 
sets of criteria used in clinical practice were proposed to identify 
patients with inflammatory back pain. Age at onset is an import‐
ant differentiating factor in back pain. However, immunosuppres‐
sants, including anti‐tumour necrosis factor (anti‐TNF), may in some 
cases suppress inflammation and therefore postpone incipient 
F I G U R E  1   Referral pattern for IBD patients with chronic back pain. Abbreviations: anti‐TNF, anti‐tumour necrosis factor; HLA, human 
leucocyte antigen; IBD, inflammatory bowel disease; IBP, inflammatory back pain; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal 
anti‐inflammatory drugs; SpA, spondyloarthritis. Percentages indicate post‐test probabilities33
Paracetamol + relative rest 
(no immobilization) 
Probability of SpA is 
moderate to high
Probability of SpA is low, consider 
other diagnosis 
Up to 2 wk of 
NSAID therapy
Referral to the 
rheumatologist









 HLA-B27 negative 
(0.32%) 
Probability of SpA is 
moderate
 HLA-B27 positive 
(20.62%) 
YES or suspicion
•  Age at onset < 40 y
•  Insidious onset
• Improvement with exercise
• No improvement in back pain with rest
• Awakening because of back pain at night
IBP if 4/5 are present
IBD therapy without efficacy in (axial)
SpA (azathioprine, vedolizumab,
corticosteroids, 5- ASA)
IBD therapy without efficacy in (axial)
SpA (anti-TNF or other biologic
therapy + detectable trough levels) 





Referral to the 
rheumatologist






Referral to physical medicine 
and rehabilitation
*Percentages are probability of spondyloarthritis 
[1]Sieper J. et al Ann Rheum Dis. 2009.
Urgent referral 
to the emergency 
room
Septic spondylodiscitis or spinal tuberculosis
HLB-B27 negative 
(1.5%)
CHRONIC BACK PAIN IN IBD PATIENTS (>12 wk)
Inflammatory back pain (IBP) [1]
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symptoms.25 To be recognised as having inflammatory back pain, pa‐
tients had to present with four out of five of the following criteria: 
age at onset <40 years, insidious onset, improvement with exercise, 
no improvement in back pain with rest or awakening because of back 
pain at night.25
Axial spondyloarthritis prevalence in IBD patients was estimated 
at 8%, which is the prevalence of symptomatic sacroiliitis in these 
patients. Asymptomatic sacroiliitis cannot be considered as axial 
spondyloarthritis and was therefore not included. When IBD pa‐
tients who present with inflammatory back pain, receive anti‐TNF 
therapy or other biologics with proven efficacy against axial spon‐
dyloarthritis and have detectable serum trough levels, onset of axial 
spondyloarthritis is improbable, although not impossible. In these 
patients, degenerative changes or fibromyalgia should be consid‐
ered. Importantly, although ustekinumab showed efficacy in a small 
open‐label study, larger randomised controlled trials have failed to 
validate these results.26‐29 In patients receiving IBD treatments not 
considered as protective against spondyloarthritis (eg azathioprine, 
corticosteroids or vedolizumab), the probability of axial spondyloar‐
thritis is moderate to high.30‐32 In these patients, NSAID therapy 
should be considered. Although all NSAIDs are equally effective in 
treating axial spondyloarthritis, the optimal dose per product is nec‐
essary (Table 1).33 Even though IBD flares in patients using NSAIDs 
were reported in case reports and observational studies, ran‐
domised controlled trials and cohort studies have produced reassur‐
ing data regarding the short‐term use of Cox‐selective NSAIDs.34‐36 
Nevertheless, in patients with uncontrolled IBD, NSAIDs should be 
used cautiously.
Based on the estimated axial spondyloarthritis prevalence in 
IBD patients (pre‐test probability) and the sensitivity and speci‐
ficity of inflammatory back pain criteria, IBD patients with chronic 
inflammatory back pain have a probability of 21.4% of having axial 
spondyloarthritis. Good response to NSAIDs results in a rise in the 
axial spondyloarthritis probability to 58.1%. Lack of response to 
NSAIDs results in a decrease in the axial spondyloarthritis proba‐
bility to 11.9%; in these patients, determining the HLA‐B27 status 
can provide an alternative route if suspicion remains high, with 
positive tests resulting in the axial spondyloarthritis probability of 
54.9%. Indeed, in patients with chronic low back pain, both HLA‐B27 
status and inflammatory back pain have proven to be good referral 
criteria.37 If inflammatory back pain is not present, the axial spon‐
dyloarthritis probability decreases to 2.8%. Even if patients without 
inflammatory back pain are positive for HLA‐B27, this probability 
only rises to 20.6%. If these patients also have a good response to 
NSAIDs, a reasonable probability of 59.5% can be reached.
The sensitivities and specificities used in this paper are based 
on a high number of estimates from several large studies in IBD. 
Nevertheless, applying different sensitivities and specificities may 
lead to different probabilities. The post‐test probabilities should be 
regarded as estimates and the validity of these algorithms should be 
tested in real‐life setting. Additionally, convergence was limited by 
the inclusion of independent variables in the algorithm.
The referral algorithm presented here can be used to evalu‐
ate IBD patients presenting with chronic back pain and to identify 
which patients should be referred to specialists based on basic 
clinical criteria and one objective laboratory test. Because of the 
need of specific expertise in interpretation of imaging, the opinion 
of the committee was that imaging is not necessary before referral. 
Indeed, X‐rays of sacroiliac joints may give false‐negative results in 
early disease stages and pelvic X‐ray interpretation has proven un‐
reliable and reader‐dependent.38 Additionally, magnetic resonance 
imaging is expensive, in high demand and only reliably interpretable 
in patients with high suspicion of spondyloarthritis. Different types 
of mechanical stress, including physiological changes induced by 
pregnancy, may mimic sacroiliitis. These imaging techniques should 
only be requested and interpreted by experienced readers with full 
knowledge of the clinical background.
In conclusion, chronic back pain is a prevalent and multi‐lay‐
ered complaint which may be influenced by therapy. This algorithm 
provides a clinical tool to differentiate whether referral is needed 
by the use of pain pattern, the patient's IBD therapy, response to 
NSAID and the HLA‐B27 status. Imaging is not essential in the ini‐
tial work‐up of any patient, as imaging quality and expertise may be 
required.
3.2 | Peripheral arthritis
Peripheral arthritis prevalence in IBD patients has been estimated 
at 13%, being highest (25%) in 20‐30‐year‐old patients.12 Arthritis 
is characterised by swelling and pain, but redness and warmth are 
also frequent. Before diagnostic investigation, it is critical to col‐
lect the patient's medical history—including concomitant symp‐
toms and previous joint flares—and to perform a complete clinical 
examination with attention to age, skin and distribution of affected 
joints.39 Symptoms of preceding enteric or genitourinary infection 
TA B L E  1   Comparable efficacy of each NSAID with 150 mg of 
diclofenac, adapted from Dougados et al33
















1208  |     VARKAS et Al.
with pathogens such as Salmonella, Shigella, Yersinia, Campylobacter, 
Clostridium or Chlamydia trachomatis should be inquired for.
Typically, peripheral spondyloarthritis has an oligoarticular 
distribution with a preferential localisation in large joints of lower 
limbs in young patients.40 In contrast, rheumatoid arthritis (RA) and 
(drug‐induced) systemic lupus erythematosus (SLE) display a more 
symmetrical distribution, generally localised on small joints of hands 
and feet.41
3.2.1 | Monoarthritis in IBD patients
Monoarthritis of a joint is a common clinical presentation in any 
population. However, the differential diagnosis is broad, and about 
half of patients with acute monoarthritis do not have a definitive 
diagnosis within 2 years.42
In the case of monoarthritis in IBD patients, exclusion of 
trauma and/or septic arthritis is essential. The latter can lead to 
joint destruction and sepsis with multiple organ failure, especially 
in patients treated with immunosuppressants or having other risk 
factors (eg, older age, diabetes mellitus, surgery or prosthetic 
joint).43 Patients with clinical indications of possible septic arthri‐
tis, such as fever, skin infection or entry wound, should be referred 
to the emergency room for blood analysis, evacuation of purulent 
material, puncture and blood culture before initiation of antibiot‐
ics. A white blood cell (WBC) count of >50 000 cells/µl with ≥90% 
neutrophils in the puncture fluid may be indicative of septic ar‐
thritis.43 Moreover, the sensitivity of a positive synovial culture is 
75%‐95% for septic arthritis.43 Other blood analyses are commonly 
performed for diagnosis purposes (WBC count, CRP, sedimenta‐
tion, uric acid, rheumatoid factor [RF] and anti‐cyclic citrullined 
peptide [anti‐CCP] levels).
Large joint monoarthritis
Since there are no established referral strategies for peripheral ar‐
thritis, the development of the decision tree for IBD patients with 
large joint monoarthritis was based on expert opinion, literature and 
experience (Figure 2).
Patients with large joint monoarthritis (knee, ankle, hip, shoulder, 
elbow or wrist) should be referred to a rheumatologist for articular 
puncture with synovial fluid evacuation (Figure 2). The purpose of 
this procedure is both therapeutic and diagnostic (cell count, culture 
and/or characterisation of crystals). Treatments, such as oral corti‐
costeroids, disease‐modifying anti‐rheumatic drugs and antibiotics, 
should not be initiated before the puncture, as they may mask dis‐
tribution, systemic inflammation and in some cases auto‐immune 
serology, thereby complicating prompt diagnosis.
F I G U R E  2   Referral pattern for IBD patients with large joint monoarthritis. Abbrevations: CRP, C‐reactive protein; IBD, inflammatory 








Perform blood analysis with WBC count, CRP, sedimentation, uric acid, RF, anti-
citrullinated protein, HLA-B27   
Large joint
Diagnostic articular puncture
200- 2000 cells/µL >2000 cells/µL
Presence of crystals




confirmation of diagnosis  
Consider pseudogout
(large joints of lower 
limbs)
Initiate NSAID therapy 





Low/absent: Optimal NSAID 
therapy [1] for up to 2 wk and 
referral to the rheumatologist 









to the emergency room
[1] Dougados et al. Ann Rheum Dis. 2011.
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Synovial fluid containing >2000 WBC/µl and >75% poly‐
morphonuclear cells is indicative of inflammatory joint disease, 
whereas synovial fluid containing <2000 WBC/µl is usually in‐
dicative of mechanical joint disease/osteoarthritis.44,45 In case 
of inflammatory joint disease, polarisation microscopy should 
be used to detect the presence of monosodium urate or calcium 
pyrophosphate dihydrate crystals, indicative of gout and pseudo‐
gout, respectively.46 If crystals are present, (pseudo)‐gout should 
be considered, local corticosteroid infiltration administered, and 
NSAID or colchicine therapy initiated. Referral to a rheumatologist 
is recommended. If no crystals are detected, B burgdorferi arthri‐
tis should be suspected in patients with current or previous ery‐
thema migrans or documented tick bites as a late manifestation of 
Lyme disease. B burgdorferi serology should not be done in every 
patient as the screening assay has high sensitivity at the expense 
of specificity.47 The suspicion of B burgdorferi will be influenced 
by the local incidence rate of Lyme's disease. When in doubt, the 
presence of DNA in the synovial fluid can be tested using poly‐
merase chain reaction. In the absence of erythema migrans history, 
peripheral spondyloarthritis should be considered and optimal 
NSAID therapy or low‐dose corticosteroids should be initiated. 
Referral to a rheumatologist is recommended. An extensive review 
of treatment of peripheral spondyloarthritis is beyond the scope of 
this article. Nevertheless, methotrexate, leflunomide and sulphas‐
alazine are slow‐acting agents, which are useless for immediate 
symptom control but may have an evaluable clinical benefit only 
after 8‐12 weeks.
Small joint monoarthritis
The approach in case of small joint monoarthritis is more difficult, 
as diagnostic puncture is rarely an option. The differential diagnosis 
is mainly based on serology (Figure S2). In RF‐ or anti‐CCP‐positive 
patients, early RA diagnosis is possible, although the most frequent 
initial presentation of RA is symmetrical polyarthritis.48 In RF‐ and 
anti‐CCP‐negative patients, osteoarthritis, peripheral spondyloar‐
thritis or gout are potential diagnoses. Nevertheless, a small portion 
of patients exhibit seronegative RA. 
In case of single arthritis at the level of the hands in combi‐
nation with bony changes of other proximal interphalangeal and 
distal interphalangeal joints, erosive hand osteoarthritis should be 
considered in middle‐aged or elderly patients.49 The presence of 
tophi or the typical localisation at the first toe metatarsophalan‐
geal joint can advocate in favour of gout, even in the absence of 
high serum uric acid in the acute phase. Importantly, monoarthritis 
F I G U R E  3   Referral pattern for IBD patients with oligo‐ or polyarticular arthritis. Abbreviations: CCP, cyclic citrullined peptide; CRP, 
C‐reactive protein; DIP, distal interphalangeal; IBD, inflammatory bowel disease; NSAIDs, nonsteroidal anti‐inflammatory drugs; RA, 
rheumatoid arthritis; RF, rheumatoid factor; SpA, spondyloarthritis; WBC, white blood cell33
Perform blood analysis with WBC count, CRP, 
sedimentation, uric acid, RF, anti-citrullinated protein, HLA-B27
Consider peripheral SpA
  (incl. reactive)
IBD disease activity
NOYES
Initiation of optimal NSAID 
therapy [1] for up to 2 wk 
and referral to rheumatologist
Consider psoriatic arthritis
Consider seronegative 
rheumatoid arthritis or other 
diagnosis such as polyarticular 
gout
Initiation of optimal NSAID 
therapy [1] for up to 2 wk 
and referral to rheumatologist
Consider rheumatoid arthritis
Initiation of optimal NSAID 
therapy [1] for up to 2 wk 
and referral to rheumatologist
Low/absent: 
Optimal NSAID 
therapy [1] for up to 2 
wk and referral to 
the rheumatologist
Moderate to high: 
Optimize control of 
underlying IBD
Anti-CCP or RF positive Anti-CCP and RF negative
DIP involvement, dactylitis or presence
 of psoriasis in patient or family
Asymmetrical distribution Symmetrical distribution
[1] Dougados et al. Ann Rheum Dis. 2011.
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in IBD patients can be the first symptom of systemic disease and 
subsequently spread towards other joints or the axial skeleton.
3.2.2 | Oligo‐ or polyarthritis in IBD patients
When several joints are involved, both distribution and auto‐im‐
mune serology are crucial. If articular puncture of a large joint is pos‐
sible, the latter should be performed to refine diagnosis (Figure 3).
3.2.3 | Arthralgia in IBD patients
Arthralgia is the presence of one or more painful joints without ob‐
jective signs of inflammation, such as swelling, redness or warmth. 
An inflammatory cause should be suspected if pain is worst during 
the night and in the morning, the patient has morning stiffness and 
feels better with exercise. A mechanical cause should be suspected 
if pain is worsening throughout the day, the patient has pain upon 
weight bearing and feels better with rest. In case of mechanical pain, 
a “wait and see” approach with paracetamol for pain relief is recom‐
mended (Figure 4 and Figure S3).
Monoarticular arthralgia
In patients with persistent monoarticular arthralgia caused by me‐
chanical pain and in patients with inflammatory arthralgia, the pres‐
ence of inflammatory activity should be assessed using ultrasound. 
In the absence of systemic inflammation, arthralgia related to over‐
use or osteoarthritis should be considered. In the case of positive 
ultrasound results, monoarthritis should be considered, and treat‐
ment with NSAIDs should be initiated. In both cases, referral to a 
rheumatologist is recommended (Figure S3).
Oligoarticular and polyarticular arthralgia
In patients with persistent oligoarticular and polyarticular arthralgia 
caused by mechanical pain, osteoarthritis and fibromyalgia should 
be considered (Figure 3).
In patients with inflammatory oligoarticular and polyarticular 
arthralgia, erythrocyte sedimentation rates should be evaluated 
(Figure 3). In patients with normal sedimentation, arthralgia is 
often related to treatment or discontinuation of therapy in ab‐
sence of systemic inflammation. Arthralgia and/or myalgia have 
been reported in 14% of azathioprine‐treated patients, of whom 
F I G U R E  4   Referral pattern for IBD patients with oligoarticular and polyarticular arthralgia. Abbreviations: ANA, antinuclear antibody; 
ANF, antinuclear factor; anti‐dsDNA, anti‐double‐stranded DNA; Cf., confer; CRP, C‐reactive protein; DD, differential diagnosis; ENA, 
extractable nuclear antigens; IBD, inflammatory bowel disease; NSAIDs, nonsteroidal anti‐inflammatory drugs; SpA, spondyloarthritis; TNF, 
tumour necrosis factor; WBC, white blood cell
Mechanical pain (worsening of pain 
throughout the day, pain upon weight 
bearing, improvement with rest)
Normal sedimentation
Concomitant corticosteroid 
therapy, recent withdrawal of 
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lupus such as lymphopenia and/
or complement activation and/or 
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OLIGOARTICULAR AND POLYARTICULAR ARTHRALGIA IN IBD PATIENTS
(RECURRENT OR LONGSTANDING [>1 MONTH])
Inflammatory (pain at night/early morning,improvement throughout the day,
morning stiffness>30min, improvement with exercise)
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68% tolerated a switch to mercaptopurine.50 Likewise, the intro‐
duction of infliximab entails a risk of transitory arthralgia,51 and 
the withdrawal of corticosteroids may involve a temporary in‐
crease of musculoskeletal symptoms.52 In patients with elevated 
sedimentation, possible culprits may be sulphasalazine or anti‐TNF 
therapies.53,54 Although immunogenicity has been described with 
all anti‐TNFs, infliximab seems to be the most immunogenic.55,56 
Importantly, anti‐TNF therapy primarily induces immunoglobulin 
(Ig) M, rather than IgG antibodies. Therefore, isolated antinuclear 
factor (ANF) elevation is of limited significance in absence of clin‐
ical symptoms. Moreover, while ANF induction is common, drug‐
induced SLE is rare.55 Drug‐induced SLE should be considered in 
patients with arthralgia who were treated with anti‐TNF and pres‐
ent with anti‐double‐stranded deoxyribonucleic acid (anti‐dsDNA) 
IgGs, hypocomplementaemia, lymphopenia, discrepant sedimen‐
tation and CRP or clinical signs of SLE. However, even in patients 
receiving anti‐TNF therapies, idiopathic SLE might have been pres‐
ent before drug initiation. Although clinical symptoms may disap‐
pear rapidly after discontinuation of the culprit drug, laboratory 
abnormalities may remain for some time. In patients with elevated 
sedimentation receiving other biologics, the response to NSAIDs 
or low‐dose corticosteroids should be evaluated prior to referral 
to a rheumatologist. The rheumatologist may consider ultrasound 
to assess the presence of inflammatory activity. In patients exhib‐
iting very high sedimentation, an infectious locus should be con‐
sidered. However, in the presence of concomitant proximal muscle 
weakness, prompt referral to a rheumatologist is recommended 
because these symptoms may be indicative of polymyalgia rheu‐
matica or other systemic auto‐immune disease.
4  | CONCLUSION
In this paper, we presented straightforward referral algorithms for 
IBD patients with spondyloarthritis symptoms, developed by a panel 
of Belgian gastroenterologists and rheumatologists. The main focus 
was on IBD patients with chronic back pain, large joint monoarthritis 
and arthralgia. The proposed strategies allow a clear evaluation for 
referral based on basic clinical criteria in combination with labora‐
tory tests to identify which patients should be referred to emergency 
room, physical medicine or rheumatologist. The proposed strategies 
are specific enough to evaluate IBD patients with joint symptoms 
without overloading rheumatologists with unnecessary referrals.
A limitation of this study is the use of different terminologies 
in gastroenterology and rheumatology regarding axial spondyloar‐
thritis, leading to a potential underestimation of the axial spondy‐
loarthritis prevalence. Moreover, we developed referral strategies 
based on expert opinion because the absence of scientific literature 
regarding the referral of IBD patients with peripheral arthritis is 
striking. Overall, the proposed algorithms may help gastroenterolo‐
gists to make a broad clinical differential diagnosis and to adequately 
select patients for referral.
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